<DOC>
	<DOCNO>NCT00989469</DOCNO>
	<brief_summary>A multicentre two-part phase I/II study evaluate response safety SORAFENIB combination irinotecan second line treatment metastatic colorectal cancer K-RAS mutation .</brief_summary>
	<brief_title>Sorafenib With Irinotecan Metastatic Colorectal Cancer ( mCRC ) K-RAS Mutation</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 Written inform consent Histologically proven adenocarcinoma colon rectum asymptomatic primary tumour surgically remove mCRC patient previously unresectable metastatic disease Patient least one tumoral lesion : measurable unidimensional way spiral scanner accord RECIST , previous irradiation area Disease progression irinotecanbased chemotherapy Disease progression one previous line chemotherapy receive metastatic situation WHO &lt; = 2 Patient mutate KRAS 12 13 codon primary tumour metastasis Adequate liver function : Bilirubin ≤ 1,5 x UNL , ASAT ou ALAT ≤ 2,5 x UNL ( &lt; 5 x UNL subject hepatic insufficiency connection hepatic metastasis ) Polynuclear neutrophils ≥ 1 500/mm3 Haemoglobin &gt; 10g/dl Platelets ≥ 100 000/mm3 Amylase lipase &lt; 1,5 x UNL Serum Creatinin &lt; 1,5 x UNL Adapted contraceptive measure treatment continue least three month end treatment Life expectancy &gt; 3 month Affiliated benefit health insurance Gilbert 's disease Brain metastases carcinomatous symptomatic meningitis Exclusive bone metastasis Previous cancer consider cured 5 year inclusion ( except basocellular skin carcinoma ) Surgery ( except diagnostic biopsy ) radiotherapy within 4 week inclusion Disorders cardiac rhythm require antiasynchronous treatment ( except beta blocker digoxine within framework chronic auricular fibrillation ) , unstable coronaropathy myocardial infarction &lt; 6 month , congestive cardiac failure &gt; Rank II NYHA ( Grade 2 ) , uncontrolled arterial hypertension Previous epilepsy crisis require long term antiepileptic treatment Previous organ transplant require immunosuppressor treatment Severe bacterial fungus infection ( &gt; Grade 2 NCI CTC version 3 ) Known HIV Infection Long term treatment know inductor CYP 3A4 like Rifampicin , Millepertuis ( hypericum perforatum ) , Phenytoin , Carbamazepin , Phenobarbital , Dexamethasone et Ketonazole Known allergy one therapeutic agent Reasons ( psychological , family , social geographical ) could compromise participation patient study Intestinal malabsorption gastrointestinal surgery able affect Sorafenib absorption . Occlusive subocclusive syndrome . Dysphagic patient patient able take treatment orally inflammatory Chronic digestive disease involve chronic diarrhoea ( NCI N+Bethesda &gt; = 1.2g ) Participation another clinical trial within 30 day start study Other concomitant experimental drug concomitant anticancer agent ( except Irinotecan Sorafenib ) Medical psychological state opinion investigator allow patient terminate study understand sign inform consent form Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>